JP2016501866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501866A5 JP2016501866A5 JP2015544173A JP2015544173A JP2016501866A5 JP 2016501866 A5 JP2016501866 A5 JP 2016501866A5 JP 2015544173 A JP2015544173 A JP 2015544173A JP 2015544173 A JP2015544173 A JP 2015544173A JP 2016501866 A5 JP2016501866 A5 JP 2016501866A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acid
- composition according
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 113
- 150000001413 amino acids Chemical class 0.000 claims description 105
- 229940024606 amino acid Drugs 0.000 claims description 78
- 235000001014 amino acid Nutrition 0.000 claims description 78
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 41
- 235000004279 alanine Nutrition 0.000 claims description 41
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 39
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 30
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 26
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 26
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 25
- 239000004473 Threonine Substances 0.000 claims description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 21
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 21
- 235000009582 asparagine Nutrition 0.000 claims description 21
- 229960001230 asparagine Drugs 0.000 claims description 21
- 239000004475 Arginine Substances 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 18
- 239000004472 Lysine Substances 0.000 claims description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 17
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 14
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 14
- 231100000241 scar Toxicity 0.000 claims description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 13
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 13
- 229960000310 isoleucine Drugs 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 12
- 235000013922 glutamic acid Nutrition 0.000 claims description 12
- 239000004220 glutamic acid Substances 0.000 claims description 12
- 239000004474 valine Substances 0.000 claims description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010039580 Scar Diseases 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 150000008575 L-amino acids Chemical class 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 230000011759 adipose tissue development Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- -1 aromatic amino acid Chemical class 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261729626P | 2012-11-25 | 2012-11-25 | |
| US61/729,626 | 2012-11-25 | ||
| US201361778084P | 2013-03-12 | 2013-03-12 | |
| US61/778,084 | 2013-03-12 | ||
| PCT/US2013/071719 WO2014082042A2 (en) | 2012-11-25 | 2013-11-25 | Peptides that stimulate subcutaneous adipogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501866A JP2016501866A (ja) | 2016-01-21 |
| JP2016501866A5 true JP2016501866A5 (cg-RX-API-DMAC7.html) | 2017-01-12 |
Family
ID=49753509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544173A Pending JP2016501866A (ja) | 2012-11-25 | 2013-11-25 | 皮下脂肪生成を刺激するペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10494402B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2922869B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016501866A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150088841A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105008396A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013347797A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2930117A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1216895A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL239008A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015123315A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014082042A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2922869B1 (en) | 2012-11-25 | 2017-09-27 | The Regents of The University of California | Peptides that stimulate subcutaneous adipogenesis |
| WO2015184125A1 (en) | 2014-05-28 | 2015-12-03 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
| EP3271383A4 (en) * | 2015-03-20 | 2019-06-12 | London Health Sciences Centre Research Inc. | GASED PEPTIDES AND USES THEREOF |
| CN107771085B (zh) * | 2015-04-17 | 2024-09-03 | 斯米克控股(美国)有限公司 | 生物缀合物及其用途 |
| KR102208853B1 (ko) * | 2018-05-08 | 2021-01-28 | 오션펩 주식회사 | 주름개선 효능을 갖는 펩티드 |
| KR102285956B1 (ko) * | 2018-11-26 | 2021-08-04 | 한국해양과학기술원 | 지방 생성을 자극하는 펩타이드, 조성 및 방법 |
| CN114081861B (zh) * | 2021-11-19 | 2023-10-31 | 和泓尚医(成都)生物科技有限公司 | 一种干细胞外泌体与复合肽抗衰制剂及其制备方法和应用 |
| GB202211043D0 (en) * | 2022-07-28 | 2022-09-14 | Univ Birmingham | Peptide agonist |
| WO2025059165A1 (en) * | 2023-09-14 | 2025-03-20 | University Of Florida Research Foundation, Incorporated | Methods of use for rhamm-derived peptides and rhamm-derived peptide mimetics |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA175473A (en) * | 1917-01-08 | 1917-03-06 | Clarence G. Cashman | Reamer head |
| GB9207949D0 (en) | 1992-04-09 | 1992-05-27 | Univ Manitoba | Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility |
| AU6081094A (en) * | 1992-12-30 | 1994-08-15 | Matthias Rath | Synthetic oligopeptides analogous to protein signal sequences methods of identification and methods of use |
| GB9420740D0 (en) | 1994-10-14 | 1994-11-30 | Univ Manitoba | Sequence of the hyaluronan receptor gene |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| CA2166155C (en) | 1995-12-27 | 2008-02-05 | Eva Anne Turley | Agents binding to hyaluronic acid binding domains and the use thereof |
| GB9607441D0 (en) | 1996-04-10 | 1996-06-12 | Univ Manitoba | Human hyaluronan receptor |
| US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| CA2237051A1 (en) | 1997-12-19 | 1999-06-19 | Eva A. Turley | Enhanced affinity hyaluronan binding peptides |
| US6211149B1 (en) | 1998-08-03 | 2001-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors of formation of protease resistant prion protein |
| GB9811962D0 (en) | 1998-06-03 | 1998-07-29 | Janssen Pharmaceutica Nv | Vertebrate homologue of UNC-53 protein of C.elegans |
| JP2002530066A (ja) | 1998-11-19 | 2002-09-17 | スミスクライン・ビーチャム・コーポレイション | Ｒｈａｍｍアンタゴニスト抗体 |
| US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
| JP2000217576A (ja) | 1999-02-02 | 2000-08-08 | Herikkusu Kenkyusho:Kk | 脂肪細胞への分化を誘導する方法、並びに脂肪細胞への分化を制御する化合物およびそのスクリーニング方法 |
| US6911429B2 (en) * | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US20070116669A1 (en) * | 2002-09-13 | 2007-05-24 | Chemokine Therapeutics Corporation | Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases |
| CA2406593A1 (en) | 2000-04-20 | 2001-11-01 | Cangene Corporation | Rhamm peptide conjugates |
| US7601825B2 (en) * | 2001-03-05 | 2009-10-13 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer |
| CA2487039A1 (en) | 2001-06-11 | 2002-12-19 | Transition Therapeutics Inc. | Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| AU2002347464A1 (en) | 2001-06-19 | 2003-01-02 | The Gouvernment Of The United States Of America, As Represented By The Secretary Department Of Healt | Anti-arthropod vector vaccines methods of selecting and uses thereof |
| US7387800B2 (en) | 2001-08-15 | 2008-06-17 | Meiji Dairies Corporation | Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| US20030170755A1 (en) | 2001-09-26 | 2003-09-11 | Ludwig Institute For Cancer Research | Tumor-associated antigen RHAMM |
| US20050008621A1 (en) | 2001-10-06 | 2005-01-13 | James Kirkland | Preadipocyte cell strains and uses therefore |
| AU2002352706A1 (en) | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| WO2003048358A1 (fr) | 2001-12-07 | 2003-06-12 | Nissui Pharmaceutical Co., Ltd. | Gene et proteine associes a la differenciation adipocytaire |
| FR2834996B1 (fr) | 2002-01-18 | 2004-12-03 | Genfit S A | Methode d'identification de substances capables de moduler la differenciation adipocytaire |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| AU2003280471B2 (en) | 2002-07-01 | 2009-04-23 | Tufts University | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| WO2004011618A2 (en) | 2002-07-29 | 2004-02-05 | Hmgene, Inc. | Methods of identifying adipocyte specific genes, the genes identified, and their uses |
| JP2007526213A (ja) | 2003-04-28 | 2007-09-13 | セコイア、ファーマシューティカルズ、インコーポレイテッド | コロナウイルスによる感染症の治療、管理および予防用の抗ウイルス剤 |
| US20040229219A1 (en) * | 2003-04-30 | 2004-11-18 | Gallaher William R. | Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) |
| CA2536504A1 (en) * | 2003-08-12 | 2005-03-03 | Glenn D. Prestwich | Heparin binding proteins: sensors for heparin detection |
| US7576052B2 (en) | 2003-10-17 | 2009-08-18 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| WO2005056039A1 (en) | 2003-12-05 | 2005-06-23 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| US8044022B2 (en) | 2005-06-08 | 2011-10-25 | Tadeusz Kolodka | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| US20090176306A1 (en) | 2005-06-10 | 2009-07-09 | Toshio Taira | Method of inducing differentiation from visceral preadipocyte to visceral adipocyte |
| US20070179085A1 (en) | 2005-07-20 | 2007-08-02 | Savani Rashmin C | Modulation of rhamm-caveolin/lipid raft interactions to affect development, responses to tissue injury, angiogenesis, tumorigenesis, metastasis and growth factor/cytokine responses |
| WO2007103770A2 (en) * | 2006-03-02 | 2007-09-13 | Ppd Biomarker Discovery Sciences, Llc | Compositions and methods for analyzing renal cancer |
| US8066691B2 (en) | 2006-04-21 | 2011-11-29 | Khouri Roger K | Method and system for preparing soft tissue for grafting, enhancing grafting results, and grafting autologous fat to soft tissue such as the breast |
| US20100323984A1 (en) | 2006-10-20 | 2010-12-23 | Laboratoires Inneov | Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding composition |
| US20100062000A1 (en) | 2006-11-21 | 2010-03-11 | The Regents Of The University Of California | Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations |
| US8715653B2 (en) * | 2006-11-21 | 2014-05-06 | The Regents Of The University Of California | Modulation of Rhamm (CD168) for selective adipose tissue development |
| EP1967524A1 (en) | 2007-03-06 | 2008-09-10 | Friesland Brands B.V. | Methods for producing ACE-inhibitory peptides from whey and peptides obtained thereby |
| WO2009036246A2 (en) | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| CA2702366C (en) | 2007-10-12 | 2016-06-07 | London Health Sciences Centre Research Inc. | Compositions affecting hyaluronic acid mediated activity |
| EP2209892A2 (en) | 2007-11-06 | 2010-07-28 | Procell Therapeutics Inc. | Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same |
| US8216828B2 (en) | 2008-05-30 | 2012-07-10 | Corning Incorporated | Assembly of cell culture vessels |
| KR101947529B1 (ko) | 2010-05-31 | 2019-02-13 | 런던 헬스 사이언시스 센터 리서치 인코포레이티드 | Rhamm 결합 펩타이드 |
| WO2012031015A1 (en) | 2010-09-01 | 2012-03-08 | The Regents Of The University Of California | Cell culture screen for agents that control adipogenesis and myofibroblast differentiation |
| US20120076810A1 (en) * | 2010-09-01 | 2012-03-29 | Poland Gregory A | Vaccinia virus polypeptides |
| TW201210608A (en) | 2010-09-07 | 2012-03-16 | Oncotherapy Science Inc | TTLL4 peptides and vaccines containing the same |
| EP2922869B1 (en) | 2012-11-25 | 2017-09-27 | The Regents of The University of California | Peptides that stimulate subcutaneous adipogenesis |
| WO2015184125A1 (en) | 2014-05-28 | 2015-12-03 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
-
2013
- 2013-11-25 EP EP13802811.3A patent/EP2922869B1/en not_active Not-in-force
- 2013-11-25 CN CN201380061413.4A patent/CN105008396A/zh active Pending
- 2013-11-25 KR KR1020157016698A patent/KR20150088841A/ko not_active Withdrawn
- 2013-11-25 JP JP2015544173A patent/JP2016501866A/ja active Pending
- 2013-11-25 AU AU2013347797A patent/AU2013347797A1/en not_active Abandoned
- 2013-11-25 RU RU2015123315A patent/RU2015123315A/ru not_active Application Discontinuation
- 2013-11-25 WO PCT/US2013/071719 patent/WO2014082042A2/en not_active Ceased
- 2013-11-25 HK HK16104706.9A patent/HK1216895A1/zh unknown
- 2013-11-25 US US14/646,298 patent/US10494402B2/en active Active
- 2013-11-25 US US14/089,445 patent/US10766927B2/en not_active Expired - Fee Related
- 2013-11-25 CA CA2930117A patent/CA2930117A1/en not_active Abandoned
-
2015
- 2015-05-25 IL IL239008A patent/IL239008A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501866A5 (cg-RX-API-DMAC7.html) | ||
| CN103096980B (zh) | 皮肤抗衰老治疗 | |
| RU2015123315A (ru) | Пептиды, стимулирующие подкожный адипогенез | |
| CN105616184B (zh) | 一种透明质酸多肽键合物面膜及其制备方法 | |
| KR101805690B1 (ko) | 화장료 조성물을 포함하는 피부 미용 키트 및 도포방법 | |
| RU2014108819A (ru) | Новые композиции и их применение | |
| ES2578636T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
| ES2932550T3 (es) | Composiciones estimulantes de células madre y métodos para tratar el melasma | |
| US12065512B2 (en) | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | |
| KR20180060537A (ko) | 피부재생 및 보습기능을 강화한 미백기능성 화장품 조성물 | |
| US20200129412A1 (en) | Silicone pad having active ingredients for skin care and against skin aging | |
| KR20170135442A (ko) | 두피의 건강 개선을 위한 화장료 조성물 및 이의 제조방법 | |
| KR101714598B1 (ko) | 비동물성 파우더를 적용한 리프팅 화장료 조성물 | |
| JP2020518593A5 (cg-RX-API-DMAC7.html) | ||
| CN116546971A (zh) | 组织源性基质因子组合物和其方法 | |
| JP2005095331A (ja) | 魚皮真皮コラーゲンを含有する発泡体シートおよびその用途 | |
| KR20240035746A (ko) | 피부 박피 조성물 | |
| CN116615218A (zh) | 治疗白癜风的药物组合物 | |
| JP2025019175A (ja) | コラーゲンハイドロゲル被膜形成剤 | |
| US20190119325A1 (en) | Cnp cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide | |
| KR101917026B1 (ko) | 피부 주름 개선 또는 예방용 화장료 조성물 | |
| JP2024543222A (ja) | 脂肪分解ペプチド | |
| KR101689875B1 (ko) | 펩타이드와 아미노산의 혼합물을 함유하는 아토피 개선용 화장료 조성물 | |
| RU2805144C1 (ru) | Рекомбинантный ангиогенин в косметических и фармацевтических композициях | |
| RU2784355C1 (ru) | Рекомбинантный ангиогенин в косметических и фармацевтических композициях |